## FACSIMILE

Date: January 28, 2002

Examiner G. Bansal

Art Unit 1640

From: Nancy J. Axelrod

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza I 2200 Clarendon Blvd., Suite 1400 Arlington, VA 22201 (U.S.A.)

(Fax: 703-243-6410)

703.308.4242

703.305.3014

703.812.5304 Writer's Direct Dial:

Telephone No.:

Facsimile No.:

Writer's Internet Address:

axelrod@mwzb.com

Re:

USSN 08/817,595

Pharmaceutical Composition for Stimulation of the Immune System

Our Ref: MARGI 15

Total No. of Pages: 5; if you do not receive all pages, please call 703-243-6333.

RECEIVED AUG 0 5 2002 TECH CENTER 1600/2900

Information contained in this facsimile communication may contain privileged and confidential information and is intended solely for the use of the addressee listed above. If you are neither the intended recipient nor the employee or agent responsible for delivering this communication to the intended recipient, you are hereby notified that any disclosure, copying or distribution of, or the taking of any action in reliance on the contents of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone on (703) 243-6333 to arrange for return of the original document to us at our cost. Thank you.

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE application of Group Art Unit: 1642 ngela TURIANO Examiner: G. Bansal Serial No. 08/817,595 Filed: April 22, 1997 PHARMACEUTICAL COMPOSITION FOR STIMULATION OF THE IMMUNE For:

REPLY

CERTIFICATION OF FACSIMILE TRANSMISSION I HEREBY CERTIFY THAT THIS PAPER IS BEING FACSIMILE TRANSMITTED TO THE PATENT AND TRADEMARK OFFICE ON THE DATE SHOWN BELOW. TYPE OR PRINT NAME OF PERSON SIGNING CERTIFICATION

Assistant Commissioner for Patents Washington, D.C. 20231

**SYSTEM** 

SIR:

In response to the Office Action dated August 28, 2001, please amend the aboveidentified application as indicated below and consider the remarks which follow:

## IN THE CLAIMS:

Please amend claims 25, 34, 36 and 39 as follows:

- 25. (Amended) A kit useful for the treatment of a carcinoma in a patient, comprising at least two containers, each comprising an extract from an animal tissue, serum or cell source different from that of the other container, wherein said extracts
  - a) comprise allogeneic or xenogeneic MHC molecules;
- b) are prepared by a) homogenizing the tissue, serum or cell source in the presence of NP40, or b) treating said source with an acid, or c) treating said source with a proteolytic enzyme; and
- c) are each effective to reduce the number of tumor cells in the patient compared to the or of tumor cells if the patient is not so treated.

  1

  MARGI 15 number of tumor cells if the patient is not soltreated.

